Patient, provider, and hospital factors associated with oral anti-neoplastic agent initiation and adherence in older patients with metastatic renal cell carcinoma-Reference-Cited by-同舟云学术

Patient, provider, and hospital factors associated with oral anti-neoplastic agent initiation and adherence in older patients with metastatic renal cell carcinoma

Published:2022-06 Issue:5 Volume:13 Page:614-623
ISSN:1879-4068
Container-title:Journal of Geriatric Oncology
language:en
Short-container-title:Journal of Geriatric Oncology

Author:

Kaye Deborah R.,Wilson Lauren E.,Greiner Melissa A.,Spees Lisa P.,Pritchard Jessica E.,Zhang Tian,Pollack Craig E.,George Daniel,Scales Charles D.,Baggett Chris D.,Gross Cary P.,Leapman Michael S.,Wheeler Stephanie B.,Dinan Michaela A.

Publisher

Elsevier BV

Subject

Geriatrics and Gerontology,Oncology

Reference46 articles.

1. Potential years of life lost due to urogenital cancer in the united states: trends from 1972 to 2006 based on data from the SEER database;Kamel;J Urol,2012

2. Efficacy of immune-checkpoint inhibitors (ICI) in the treatment of older adults with metastatic renal cell carcinoma (mRCC) - an International mRCC Database Consortium (IMDC) analysis;Araujo;J Geriatr Oncol,2021

3. Racial disparity in renal cell carcinoma patient survival according to demographic and clinical characteristics;Chow;Cancer,2013

4. Racial disparities in survival among patients with advanced renal cell carcinoma in the targeted therapy era;Rose;Cancer,2016

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Investigating adherence to tyrosine kinase inhibitors in renal cancer;Journal of Oncology Pharmacy Practice;2024-06-05

2. A scoping review of racial, ethnic, socioeconomic, and geographic disparities in the outcomes of older adults with cancer;Journal of the American Geriatrics Society;2024-04-09

3. Drug costs: acquisition costs are critical but not the entire story of financial toxicity;BJU International;2023-06-11

4. End-of-Life Care for Patients With Metastatic Renal Cell Carcinoma in the Era of Oral Anticancer Therapy;JCO Oncology Practice;2023-02